A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer

NCT07466901 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Cervical Cancer
Radical Surgery
Adjuvant Therapy

Interventions

DRUG: Camrelizumab
DRUG: famotinib

Sponsor

Jin LI